İnternal Mammaryal Radyoterapi Uygulanmalı Mı
Özet
Meme kanserinde lokal-bölgesel tedavinin ve adjuvan radyoterapinin önemli bir bileşeni olan internal mammaryal nod (İMN) alanının ışınlanması, klinik pratikte halen en çok tartışılan konulardan biridir. Anatomi ve drenaj özellikleri bakımından bu bölge, sternum kenarında yer almakta olup memenin her kadranından metastaz alabilmektedir. Klinik ve patolojik evrelemede prognozu doğrudan etkileyen İMN tutulumu, özellikle aksiller lenf nodu pozitifliği, büyük tümör çapı ve medial yerleşimli tümörlerde yüksek oranlarda izlenmektedir. Erken evre ve nod pozitif hastaları inceleyen M.A. 20, EORTC 22922/10925 ve Danimarka çalışması gibi büyük randomize araştırmalar ile meta-analizler, İMN alanını içeren rejyonel nodal ışınlamanın hastalıksız sağkalım ile uzak metastazsız sağkalımı anlamlı derecede iyileştirdiğini ve meme kanserine bağlı mortaliteyi azalttığını göstermektedir. Buna karşın, tedavi planlamasında kalp ve akciğer üzerindeki olası toksisite riskleri dikkatle değerlendirilmelidir. NCCN ve ASCO gibi güncel kılavuzlar, risk faktörlerine göre İMN radyoterapisini farklı kategorilerde önerirken, modern radyoterapi teknikleri ve internal mammaryal sentinel lenf nod biyopsisi (İM-SLNB) gibi yöntemler hastaya özgü, optimize edilmiş tedavi kararlarının verilmesini kolaylaştırmaktadır.
Breast cancer regional nodal irradiation including the internal mammary node (IMN) area remains a highly debated topic in clincal practice. Located along the sternum, the IMN chain receives lymphatic drainage from all breast quadrants, and its involvement signifies a poor prognosis. IMN metastasis correlates with axillary lymph node positivity, larger tumor size, and medial or central tumor location. Large randomized clinical trials such as M.A. 20, EORTC 22922/10925, and the Danish cohort study, along with comprehensive meta-analyses, demonstrate that adding IMN radiotherapy significantly enhances disease-free and distant metastasis-free survival while substantially reducing breast cancer-specific mortality. However, these clinical benefits must be carefully weighed against potential pulmonary and cardiac toxicities. While major guidelines like NCCN and ASCO offer distinct recommendations based on the number of positive axillary nodes and tumor characteristics, recent advancements in radiotherapy techniques and internal mammary sentinel lymph node biopsy (IM-SLNB) facilitate more individualized, precise patient selection, effectively minimizing long-term side effects while maximizing survival outcomes.
Referanslar
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Özmen V. Breast cancer in Turkey: Analysis of 20.000 patients with breast cancer. Eur J Breast Health. 2019;15:141- 146
Cong BB, Cao XS, Cao L, et al. Internal mammary lymph nodes radiotherapy of breast cancer in the era of individualized medicine. Oncotarget 2017; 8: 81583–90
Stibbe EP: Internal mammary lymphatic glands. J Anat 1918; 52:257–264
McDonald J, Haagensen CD, Stout AP: Metastasis from mammary carcinoma to the supraclavicular and internal mammary lymph nodes. Surgery 1953; 34:521–542
Suami H, Pan WR, Mann GB, Taylor GI. The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study. Ann Surg Oncol. 2008;15:863–71
Jochelson MS, Lebron L, Jacobs SS, Zheng J, Moskowitz CS, Powell SN, et al. Detection of internal mammary adenopathy in patients with breast cancer by PET/CT and MRI. AJR Am J Roentgenol. 2015;205:899–904
Savaridas SL, Spratt JD, Cox J. Incidence and potential significance of internal mammary lymphadenopathy on computed tomography in patients with a diagnosis of primary breast cancer. Breast Cancer (Auckl). 2015;9:59–65.
Mack M, Chetlen A, Liao J. Incidental internal mammary lymph nodes visualized on screening breast MRI. AJR Am J Roentgenol. 2015;205:209–14.
Cheon H, Kim HJ, Lee SW, Kim DH, Lee CH, Cho SH, et al. Internal mammary node adenopathy on breast MRI and PET/ CT for initial staging in patients with operable breast cancer: prevalence and associated factors. Breast Cancer Res Treat. 2016;160:523–30
Estourgie, S. H., Nieweg, O. E., Olmos, R. A. V., Rutgers, E. J. T., & Kroon, B. B. Lymphatic drainage patterns from the breast. Annals of surgery, 2004; 239(2), 232.
Huang O, Wang L, Shen K, et al: Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: Analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat 2008;107:379–387
Veronesi, U., Marubini, E., Mariani, L., Valagussa, P., & Zucali, R. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. European Journal of Cancer, 1999; 35(9), 1320-1325.
Chen, R. C., Lin, N. U., Golshan, M., Harris, J. R., & Bellon, J. R. Internal mammary nodes in breast cancer: diagnosis and implications for patient management—a systematic review. Journal of clinical oncology, 2008;26(30), 4981-4989.
Poortmans PM, Kirkove C, Limbergen EV, Budach V, Struikmans H, Collette L, et al. Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. N Engl J Med 2015; 373: 317-327
Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.J Clin Oncol. 2004;22(21):4247-4254
Veronesi U, Arnone P, Veronesi P, Galimberti V, Luini A, Rotmensz N, Botteri E, Ivaldi GB, Leonardi MC, Viale G, Sagona A, Paganelli G, Panzeri R, et al. The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series. Ann Oncol. 2008; 19:1553–1560
Qiu PF, Cong BB, Zhao RR, Yang GR, Liu YB, Chen P, Wang YS. Internal mammary sentinel lymph node biopsy with modified injection technique: high visualization rate and accurate staging. Medicine (Baltimore). 2015; 94: e1790.
Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015; 373:307–316.
Poortmans, P. M., Weltens, C., Fortpied, C., Kirkove, C., et al. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. The Lancet Oncology, 2020;21(12), 1602-1610.
Hennequin C, Bossard N, Servagi-Vernat S, Maingon P, Dubois JB, Datchary J, Carrie C, Roullet B, Suchaud JP, Teissier E, Lucardi A, Gerard JP, Belot A, et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2013; 86:860–866
Thorsen LB, Offersen BV, Danø H, Berg M, Jensen I, Pedersen AN, Zimmermann SJ, Brodersen HJ, Overgaard M, Overgaard J. DBCG-IMN: A population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2016; 34:314–320.
Budach W, Bölke E, Kammers K, Gerber PA, Nestle Krämling C, Matuschek C. Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update. Radiat Oncol. 2013; 10:258.
Kim, Yong Bae, et al. "Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial." JAMA oncology 8.1 (2022): 96-105.
Duane FK, McGale P, Teoh S, et al. International variation in criteria for internal mammary chain radiotherapy. Clin Oncol (R Coll Radiol) 2019; 31: 453–61
